Phase 2 ASCEND trial of solengepras, a novel, non-dopaminergic GPR6 inhibitor, showed evidence of potential benefit in ...
Stimulation of the A13 brain region restores motor function in Parkinson's disease mouse models by alleviating bradykinesia and akinesia.
The combination of ADG126 and pembrolizumab (Keytruda) delivered a durable clinical benefit with a meaningful overall ...
Nebraska Examiner reports on the Common Cause lawsuit.
Following its Type A meeting with the FDA, Replimune reported that a forward pathway “has not been determined” to obtain ...
What could've ended in silence became a turning point—not just for De Lagarde, but for how the U.K. investment firm began ...
As accusations of genocide in Gaza mount against Israel, NPR looks at how the term is defined legally and why previously ...
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints.
Introduction The gig economy is a promising arena to reduce unemployment and provide other benefits such as the opportunity to earn supplemental income. Like all other forms of work, the gig space ...
Our whole mission is to help our customers spend less,” Glyman told Fortune. That goal has made the company one of the hottest startups on the market.
The Manila Times on MSN
Planetary health check warns risk of 'destabilising' Earth systems
Humans are gambling the very stability of Earth's life support systems, scientists said Wednesday, warning that ocean acidity ...
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback